卢非酰胺

卢非酰胺（CAS 106308-44-5）的公开数据库记录，列此仅供独立核对。

危险化学品分类与危害说明

物理形态与操作说明

• Insoluble
• 148.6 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]
• At high concentrations will inhibit action of mGluR5 subtype receptors thus preventing the production of glutamate.

公开数据库收录的理化数据

这个物质在各数据库里的编号

数据库记载的用途

• Use (kg; approx.) in Germany (2009): >250
• Consumption (g per capita; approx.) in Germany (2009): 0.00305
• Adjunct therapy for treatment of seizures associated with Lennox-Gastaut syndrome.
• Rufinamide is a triazole derivative drug structurally unrelated to any other anti-seizure drug (ASD). It was first developed in 2004 and later granted orphan drug status in October 2004. It was first marketed in Europe in January 2007. It was approved by the US FDA on November 14, 2008, for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS). Interestingly, it was the first anti-seizure medication to reach the US market with a pediatric indication prior to approval for adults.
• Rufinamide is a unique anticonvulsant that is used in combination with other agents as therapy of severe forms of seizure disorders. Rufinamide therapy is associated with a low rate of transient serum enzyme elevations and with rare instances of clinically apparent liver injury.
• Breast Feeding; Lactation; Anticonvulsants;

它在各数据库里的别名

Rufinamide; 106308-44-5; Inovelon; Banzel; 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide; CGP-33101; Cgp 33101; RUF 331; RUF-331; 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide; Rufinamida; DTXSID1046506; E-2080; E2080; WFW942PR79; E 2080

计算机算出的分子描述符

数据库摘要

Rufinamide · CAS 106308-44-5 · C10H8F2N4O. UNII WFW942PR79. LogP: 0.835; LogP: 0.88.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。